Original articleEffectiveness of BCG vaccination in england and wales in 1983
References (11)
- et al.
Changes in tuberculosis notification rates in the white ethnic group in England between 1971 and 1978/79
British Journal of Diseases of the Chest
(1984) - et al.
The current value of tuberculin testing and BCG vaccination in school children
British Journal of Diseases of the Chest
(1986) BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life
Bulletin of the World Health Organization
(1972)- et al.
BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life
British Medical Journal
(1977) Present effectiveness of BCG vaccination in England and Wales
Tubercle
(1975)
Cited by (53)
In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy
2016, VaccineCitation Excerpt :Monocyte monolayers were infected with M. microti for 24 h and the change in number of live bacteria in monolayers and supernatants over 4 days quantified by colony counts. Mycobacterial growth was significantly inhibited at days 3 and 4 of the culture using cells from post- compared with pre-BCG vaccination, reflecting the protective effect of BCG vaccination in this population [21]. The same group later applied this assay to a study of PPD-negative children receiving BCG vaccination in Chingleput, India [22].
Assessment of the need for universal BCG vaccination of children in Taipei
2009, Public HealthCitation Excerpt :Inconsistent results from several controlled trials of BCG vaccine have cast doubts over its efficacy. Some studies have demonstrated that BCG vaccine gives good protection against TB,2 but other studies have shown very little protection.3 Moreover, variation in the protective effect of the vaccine has been observed not only between trials but also between different sites of disease.
The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-γ producing cells ex vivo
2007, VaccineCitation Excerpt :Tuberculosis (TB) is responsible for a high morbidity and mortality, especially in developing countries, and the current HIV pandemic has increased the TB disease burden. The global incidence of TB is rising by about 1% per annum despite the widespread coverage of BCG vaccination, which has variable efficacy–being at its worst in adults in developing countries [1–6]. Several factors have been suggested as potential contributors to this discrepancy including variations in study design, BCG strain, nutritional status and age at vaccination [2,7,8].
BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: Two randomised controlled studies
2002, LancetCitation Excerpt :We report two studies carried out in parallel in Karonga District, Malawi and in the south-east of the UK, to examine natural and BCG-attributable cytokine and skin test responses to mycobacterial antigens. The populations were selected because of extensive evidence that the same (Glaxo 1077) BCG vaccine provides appreciable protection against pulmonary tuberculosis in the UK13,14 but no protection in Karonga, Malawi.15 We present findings for pre-vaccination and post-vaccination IFN-γ and delayed type hypersensitivity (DTH) skin test responses to M tuberculosis PPD in these populations.